Mid career · publishing since 2007Rising activity
Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia ResearchAcute Lymphoblastic Leukemia researchCAR-T cell therapy researchHematopoietic Stem Cell Transplantation
Publications
349
Citations
2,809
Est. group size
—
Recurring co-author estimate
Active years
20
Publishing since 2007
In context
Among 4,491 mid career Medicine PIs within our index
Citations: 2,809p25 240 · p75 1,552 · cohort median 614
Publications / year (recent): 44.6p25 1.8 · p75 7.2 · cohort median 3.4
Typically publishes in teams of ~13 · 6% small-team papers (≤3 authors) · across 78 venues
Publication cadence
Publications per year over the last 10 years — averaging 44.6/year recently
Recent publications
- MYD88 variants in chronic lymphocytic leukemia exhibit distinct biological behaviors and prognostic implications
Leukemia · 2026
- USP28 promotes multiple myeloma progression by regulating NF-κB signaling through KIF20B
Blood · 2025
- Establishment of differential diagnostic model for ET and pre-PMF based on circulating CD34+ cells and its clinical significance
Blood · 2025
- Efficacy and mechanism of BTK degrader nx-5948 in secondary hemophagocytic lymphohistiocytosis
Blood · 2025
- Efficacy and safety of rocbrutinib, the fourth generation bruton's tyrosine kinase inhibitor, in patients with BTK inhibitor pre-treated relapsed or refractory Mantle Cell Lymphoma: Results from a Phase II rock-1 trial
Blood · 2025
- Preliminary efficacy and safety of TT-01488, a novel, non-covalent, reversible BTK inhibitor, in patients with relapsed/refractory mantle cell lymphoma
Blood · 2025
- Supplementary Table S1 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025
- Supplementary Table S3 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025
- Supplementary Figure S1 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025
- Supplementary Table S2 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025
- Supplementary Figure S3 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025
- Supplementary Figure S2 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025
- Supplementary Table S6 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025
- Supplementary Table S4 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025
- Supplementary Table S5 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025
Publishes in
- Blood×39
- PubMed×29
- Annals of Hematology×10
- Journal of Clinical Oncology×10
- Hematological Oncology×8
Similar researchers
By research-topic overlap
- Radhika Takiar
Medicine · University of Michigan
- Emily Dotson
Medicine · The Ohio State University
- Anna B. Owczarczyk
Medicine · University of Michigan
- Beth Christian
Medicine · The Ohio State University
- Dahlia Sano
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile